Internal Medicine/Cardiology

 

Prakash Deedwania, MD

Clinical Professor of Medicine, UCSF

 

 

 

 

 

 


 

 

  Medical School University of Rajasthan, Jaipur, India
 

Residency:

VA Medical Center, Bronx /Mt. Sinai School of Medicine, New York
  Fellowship: University of Illinois
  Board Certified: Internal Medicine
Cardiovascular Diseases
Pulmonary Diseases
  Awards and Recognition:

Associate Staff Member of the Cardiovascular Research Institute,

UCSF Election to the Council of Clinical Cardiology of the World Heart Federation

     
  Publications: well over 200, including:
   

 

 

PEER REVIEWED ARTICLES IN REFEREED JOURNALS

 

  1. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J CardioI1999;83:507-514.

  2. Deedwania P and the Amlodipine Study Group. Anti-ischemic effects of amlodipine in patients with stable coronary disease and ischemia during daily life. Am J CardioI1999;83:l117-1119.

  3. Deedwania PC. Endothelin, The Bad Actor in the Play: A Marker or Mediator of Cardiovascular Disease. J Am ColI CardioI1999;33(4):939-942.

  4. The MERIT-HF Study Group (Deedwania, Gottlieb S, Principal Investigators, USA). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999;353 :2001-2007.

  5. Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer A. Hardison JD, Cushing DJ. Michelson EL. for the CANDLE Study Group. Comparative effects of candesartan and losartan in patients with systemic hypertension. Heart Disease 1999; 1 :52-57.

  6. Hutchison SJ, Sudhir K, Sievers RE, Zhu BQ, Sun YP , Chou TM. Chatterjee K, Deedwania PC, Cooke JP, Glantz SA, Parmley WW, Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke. Hypertension 1999;34:44-50.

  7. Rubins HB, Deedwania PC et al.(for the Veterans Affairs High- Density Lipoprotein Cholesterol Intervention Trial Study Group (VA-HIT Group)). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Eng J Med 1999;341 :410-418.

  8. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: Executive summary and recommendations. A report on the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Circulation 1999;100:886-893.

  9. Matalka MS, Deedwania PC. Do NSAIDs attenuate the therapeutic effect of ACE inhibitors in patients with heart failure? CHF 1999;5:228-234.

  10. The MERIT-HF Study Group (Deedwania PC, Gottlieb S, Principal Investigators. USA). Hospitalizations, symptoms of functional capacity, and quality of life in the metoprolol CR/XL randomized intervention trial in congestive heart failure. New Engl J Med 1999;353:2001- 2007.

  11. Hjalmarson A, Goldstein S, Deedwania PC, et al., for the International Steering Committee for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure. JAMA 2000;283:1295-1302.

  12. Wong M, Germanson T, Taylor WR, Cohen IS, Perry G, Baruch L, Deedwania P, Lopez B, Cohn IN. Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. J Cardiac Failure 2000;6:19-28.

  13. Deedwania PC. Silent myocardial ischaemia in the elderly. Drugs & Aging 2000; 16:381-389.

  14. Deedwania PC. Hypertension and diabetes; new therapeutic options. Arch Intern Med 2000:160:1585-1594.

  15. OPUS- TIMI 16 Investigators (PC. Deedwania, Principal Investigator). Oral glycoprotein IIb/Illa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS- TIMI 16) Trial. Circulation 2000;102:149-156.

  16. Matalka MS, Deedwania PC. Atrial fibrillation in patients with heart failure: Pharmacologic options. CHP 2001:7;22-29.

  17. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001;285:1585-1591.

  18. Wedel H, DeMets D, Deedwania P, et a1., on behalf of the MERIT-HF Study Group. Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT- HF trial. Am Heart J 2001: 142(3):502-511.

  19. Sun YP, Zhu BQ, Browne AEM, Pulukurthy S, Chou TM, Deedwania PC, et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Therapeut 2001:6(2):175-181.

  20. Fu Y, Deedwania PC, Pharmacotherapy of hypertension in patients with diabetes mellitus. Expert Opin Pharmacother 2001:2(11):1805-1816.

  21. Chandalia M, Deedwania PC: Coronary heart disease and risk factors in Asian Indians. Adv Exp Med Biol 2001; 498: 27-34.

  22. Deedwania PC: Pharmacotherapy of hypertension in patients with diabetes mellitus. Expert Opin Pharmacother 2001; 2(11): 1805-16.

  23. Deedwania PC, Stone PH: Ambulatory electrocardiographic monitoring for myocardial ischemia. Curr Probl Cardiol 2001; 26(11): 680-727.

  24. Deedwania P: Global risk assessment in the presymptomatic patient. Am J Cardiol 2001; 88(7B): 17J-22J.

  25. Deedwania PC: Silent ischemia predicts poor outcome in high-risk healthy men. J Am Coll Cardiol 2001; 38(1): 80-3.

  26. Matalka MS, Deedwania PC: Atrial fibrillation in patients with heart failure: pharmacologic options. Congest Heart Fail 2001; 7(1): 22-29.

  27. Perkiomaki JS, Zareba W, Ruta J, et al.: Fractal and complexity measures of heart rate dynamics after acute myocardial infarction. Am J Cardiol 2001; 88(7): 777-81.

  28. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. Jama 2001; 285(12): 1585-91.

  29. Sun YP, Zhu BQ, Browne AE, et al.: Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001; 6(2): 175-81.

  30. Wedel H, Demets D, Deedwania P, et al.: Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142(3): 502-11.

  31. Deedwania PC: Clinical significance of cardiovascular dysmetabolic syndrome. Curr Control Trials Cardiovasc Med 2002; 3(1): 2.

  32. Deedwania PC: The changing face of hypertension: is systolic blood pressure the final answer? Arch Intern Med 2002; 162(5): 506-8.

  33. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC: Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105(13): 1585-91.

  34. Gottlieb SS, Fisher ML, Kjekshus J, et al.: Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 2002; 105(10): 1182-8.

  35. Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ: Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39(9): 1456-63.

  36. Khand AU, Cleland JG, Deedwania PC: Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 2002; 7(3): 267-83.

  37. Matalka MS, Ravnan MC, Deedwania PC: Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002; 144(4): 674-7.

  38. Ravnan SL, Ravnan MC, Deedwania PC: Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail 2002; 8(2): 80-5.

  39. Reynolds HQ, Deedwania PC: Treating hypertension in patients with diabetes. Nurse Pract 2002; 27(7): 11-21; quiz 21-3.

  40. Spertus JA, Tooley J, Jones P, et al.: Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J 2002; 143(4): 636-42.

  41. Deedwania PC: Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep 2003; 3(4): 289-92.

  42. Deedwania PC: The key to unraveling the mystery of mortality in heart failure: an integrated approach. Circulation 2003; 107(13): 1719-21.

  43. Deedwania PC: Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease. Am J Cardiol 2003; 91(1): 68-71.

  44. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41(1): 159-68.

  45. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107(1): 149-58.

  46. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J: Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol 2003; 92(4): 478-80.

  47. Gupta R, Sharma AK, Gupta VP, Bhatnagar S, Rastogi S, Deedwania PC: Increased variance in blood pressure distribution and changing hypertension prevalence in an urban Indian population. J Hum Hypertens 2003; 17(8): 535-40.

  48. Ravnan SL, Deedwania PC: The rational use of diuretics in heart failure. Curr Cardiol Rep 2003; 5930:237-42

 

 

INVITED REVIEWS AND PUBLICATIONS

 

  1. Deedwania P, Member, Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardlol 1999;83(2A): lA- 38A.

  2. Deedwania PC, Larosa JC, Superko HR, Article Consultants, Lipid-lowering Drug Therapy from A to Z. Patient Care. February 28, 1999, 13-21.

  3. Deedwania PC, LaRosa JC, Superko HR. Lipid-lowering drug therapy from A to Z. Patient Care Supplement, February 28, 1999.

  4. Deedwania PC, Gheorghiade M. Therapeutic options for effective management of coronary artery disease. Institute for Continuing Healthcare Education, May 1999.

  5. Deedwania PC. Commentary, Endothelial Function Forum. Cardiology Review, August 2000.

  6. Deedwania PC. Endothelium: A new target for cardiovascular therapeutics. J Am CoIl Cardiol 2000;35:67-70.

  7. Deedwania PC. Hypercholesterolemia: Is lipid-lowering worthwhile for older patients? Geriatrics 2000;55 :22-28.

  8. Deedwania PC. Principal Investigator, MERIT-HF Study Group. Screening, endpoint, classification, and safety monitoring in the Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Eur J Heart Failure, August 2000.

  9. Mehta KR, Deedwania PC. The benefits of beta-blocker therapy in myocardial ischemia. Resident & Staff Physician 2000;46:9-11,20.

  10. Sica DA, Deedwania PC. COX-2 inhibition: A cautionary note in congestive heart failure. HF 2000;6:272-276.